Genmab Historical Income Statement

GMAB Stock

USD 20.65 0.18 0.88%

Historical analysis of Genmab AS income statement accounts such as Selling General Administrative of 3.5 B or Other Operating Expenses of 11.7 B can show how well Genmab AS performed in making a profits. Evaluating Genmab AS income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Genmab AS's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Genmab AS latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Genmab AS is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.

About Genmab Income Statement Analysis

Genmab AS Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Genmab AS shareholders. The income statement also shows Genmab investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Genmab AS Income Statement Chart

At present, Genmab AS's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 3.5 B, whereas Interest Expense is forecasted to decline to about 16.6 M.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses Non Operating Income Net Other

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Genmab AS. It is also known as Genmab AS overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Genmab AS's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Genmab AS current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.At present, Genmab AS's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 3.5 B, whereas Interest Expense is forecasted to decline to about 16.6 M.

	2021	2022	2023	2024 (projected)
Interest Expense	13M	21M	27M	16.6M
Depreciation And Amortization	250M	290M	240M	252M

Interest Expense Depreciation And Amortization

Genmab AS income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Cost Of Revenue	Tax Provision	Interest Income	Net Income From Continuing Ops	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		-0.03	0.75	0.81	0.91	0.91	0.84	0.92	0.82	0.94	0.32	0.92	0.95	0.88	0.89	0.21	0.94	0.7	0.92	0.69	0.91
Interest Expense	-0.03		0.06	0.03	-0.13	-0.03	0.01	-0.03	0.02	-0.04	0.56	-0.16	0.0	-0.03	-0.04	0.28	0.0	0.04	-0.08	0.04	0.02
Selling General Administrative	0.75	0.06		0.99	0.81	0.81	0.98	0.81	0.99	0.85	0.32	0.82	0.87	0.96	0.95	0.61	0.77	0.92	0.75	0.91	0.84
Other Operating Expenses	0.81	0.03	0.99		0.85	0.85	1.0	0.85	1.0	0.88	0.29	0.86	0.91	0.98	0.97	0.6	0.81	0.94	0.79	0.93	0.86
Operating Income	0.91	-0.13	0.81	0.85		0.99	0.87	0.99	0.86	0.99	0.08	0.99	0.96	0.94	0.95	0.28	0.92	0.72	0.96	0.71	0.93
Ebit	0.91	-0.03	0.81	0.85	0.99		0.86	1.0	0.85	0.99	0.17	0.99	0.95	0.94	0.94	0.25	0.92	0.71	0.96	0.7	0.94
Research Development	0.84	0.01	0.98	1.0	0.87	0.86		0.86	1.0	0.9	0.29	0.87	0.93	0.98	0.98	0.58	0.83	0.93	0.81	0.93	0.87
Ebitda	0.92	-0.03	0.81	0.85	0.99	1.0	0.86		0.86	0.99	0.17	0.99	0.96	0.94	0.94	0.25	0.93	0.71	0.96	0.7	0.94
Total Operating Expenses	0.82	0.02	0.99	1.0	0.86	0.85	1.0	0.86		0.89	0.3	0.86	0.91	0.98	0.98	0.57	0.82	0.93	0.8	0.93	0.87
Income Before Tax	0.94	-0.04	0.85	0.88	0.99	0.99	0.9	0.99	0.89		0.23	0.99	0.98	0.96	0.96	0.28	0.95	0.74	0.97	0.73	0.96
Total Other Income Expense Net	0.32	0.56	0.32	0.29	0.08	0.17	0.29	0.17	0.3	0.23		0.14	0.3	0.22	0.23	0.0	0.32	0.15	0.2	0.15	0.35
Net Income	0.92	-0.16	0.82	0.86	0.99	0.99	0.87	0.99	0.86	0.99	0.14		0.95	0.94	0.95	0.23	0.92	0.71	0.97	0.7	0.94
Income Tax Expense	0.95	0.0	0.87	0.91	0.96	0.95	0.93	0.96	0.91	0.98	0.3	0.95		0.96	0.97	0.36	0.96	0.78	0.93	0.77	0.97
Total Revenue	0.88	-0.03	0.96	0.98	0.94	0.94	0.98	0.94	0.98	0.96	0.22	0.94	0.96		1.0	0.49	0.88	0.89	0.89	0.88	0.92
Gross Profit	0.89	-0.04	0.95	0.97	0.95	0.94	0.98	0.94	0.98	0.96	0.23	0.95	0.97	1.0		0.46	0.89	0.88	0.9	0.87	0.93
Cost Of Revenue	0.21	0.28	0.61	0.6	0.28	0.25	0.58	0.25	0.57	0.28	0.0	0.23	0.36	0.49	0.46		0.21	0.71	0.17	0.72	0.27
Tax Provision	0.94	0.0	0.77	0.81	0.92	0.92	0.83	0.93	0.82	0.95	0.32	0.92	0.96	0.88	0.89	0.21		0.64	0.96	0.63	0.98
Interest Income	0.7	0.04	0.92	0.94	0.72	0.71	0.93	0.71	0.93	0.74	0.15	0.71	0.78	0.89	0.88	0.71	0.64		0.61	1.0	0.67
Net Income From Continuing Ops	0.92	-0.08	0.75	0.79	0.96	0.96	0.81	0.96	0.8	0.97	0.2	0.97	0.93	0.89	0.9	0.17	0.96	0.61		0.6	0.96
Net Interest Income	0.69	0.04	0.91	0.93	0.71	0.7	0.93	0.7	0.93	0.73	0.15	0.7	0.77	0.88	0.87	0.72	0.63	1.0	0.6		0.66
Reconciled Depreciation	0.91	0.02	0.84	0.86	0.93	0.94	0.87	0.94	0.87	0.96	0.35	0.94	0.97	0.92	0.93	0.27	0.98	0.67	0.96	0.66

Click cells to compare fundamentals

Genmab AS Account Relationship Matchups

Genmab AS income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	259M	246M	250M	290M	240M	252M
Interest Expense	7M	10M	13M	21M	27M	16.6M
Selling General Administrative	342M	661M	1.3B	2.7B	3.3B	3.5B
Other Operating Expenses	2.7B	3.8B	5.5B	8.2B	11.2B	11.7B
Operating Income	2.6B	6.3B	3.0B	6.4B	5.3B	5.6B
Ebit	2.6B	6.3B	2.9B	6.8B	5.3B	5.6B
Research Development	2.4B	3.1B	4.2B	5.6B	7.6B	8.0B
Ebitda	2.9B	6.5B	3.1B	7.0B	5.6B	5.8B
Total Operating Expenses	2.7B	3.8B	5.5B	8.2B	10.9B	11.5B
Income Before Tax	2.9B	5.9B	4.0B	7.0B	5.6B	5.9B
Total Other Income Expense Net	221M	(409M)	965M	768M	316M	190.7M
Net Income	2.2B	4.8B	3.0B	5.5B	4.4B	4.6B
Income Tax Expense	693M	1.1B	975M	1.5B	1.3B	1.3B
Total Revenue	5.4B	10.1B	8.5B	14.6B	16.5B	17.3B
Gross Profit	5.4B	10.1B	8.5B	14.6B	15.9B	16.7B
Tax Provision	693M	1.1B	975M	1.5B	1.3B	690.5M
Interest Income	348M	184M	197M	324M	939M	986.0M
Net Income From Continuing Ops	2.2B	4.8B	3.0B	5.5B	4.4B	2.9B
Net Income Applicable To Common Shares	2.2B	4.8B	3.0B	5.5B	6.4B	6.7B
Net Interest Income	334M	174M	184M	303M	912M	957.6M
Reconciled Depreciation	139M	259M	248M	362M	295M	229.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:

How To Invest In Genmab

Details

Is Genmab Stock a good investment?

Details

What is Genmab AS's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.38)

Earnings Share

1.02

Revenue Per Share

30.6997

Quarterly Revenue Growth

0.176

Return On Assets

0.1095

The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Genmab Historical Income Statement

About Genmab Income Statement Analysis

Genmab AS Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Genmab AS income statement Correlations

Genmab AS Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Genmab AS income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Total Operating Expenses	+ 1.0	Research Development
Gross Profit	+ 1.0	Total Revenue
Net Interest Income	+ 1.0	Interest Income

Net Income	- 0.16	Interest Expense
Operating Income	- 0.13	Interest Expense
Net Income From Continuing Ops	- 0.08	Interest Expense
Gross Profit	- 0.04	Interest Expense
Income Before Tax	- 0.04	Interest Expense
Total Revenue	- 0.03	Interest Expense